Overview

PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer

Status:
Not yet recruiting

Trial end date:
2029-05-01

Target enrollment:

Participant gender:

Summary

DEMETHER is a phase II trial exploring the maintenance of trastuzumab and pertuzumab fixed dose combination (FDC) for subcutaneous administration (SC, PHESGO) following trastuzumab deruxtecan (T-DXd) as induction treatment for HER2-positive unresectable locally recurrent or metastatic breast cancer (MBC) patients.

Phase:

Phase 2

Details

Lead Sponsor:

MedSIR

Collaborator:

Hoffmann-La Roche

Treatments:

Pertuzumab
Trastuzumab
Trastuzumab deruxtecan